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Abstract 
Blood components play key roles in the modulation of the wound healing process and, 
together with the provisional fibrin matrix ability to selectively bind bioactive molecules 
and control its spatial-temporal presentation, define the complex microenvironment that 
characterize this biological process. As a biomimetic approach, the use of blood 
derivatives in regenerative strategies has awaken as a source of multiple therapeutic 
biomolecules. Nevertheless, and despite their clinical relevance, blood derivatives have 
been showing inconsistent therapeutic results due to several factors, including proper 
control over their delivery mechanisms. Herein, we highlight recent trends on the use 
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biomaterials to protect, sequester and deliver these pools of biomolecules in tissue 
engineering and regenerative medicine approaches. Particular emphasis is given to 
strategies that enable to control their spatiotemporal delivery and improve the selectivity 
of presentation profiles of the biomolecules derived from blood derivatives rich in 
platelets. Finally, we discussed possible directions for biomaterials design to potentiate 
the aimed regenerative effects of blood derivatives and achieve efficient therapies. 
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1.   Introduction 
Wound healing following injury is a highly complex and dynamic process that can 
either lead to the formation of a scarred (repaired) or a regenerated tissue, depending on 
the multicellular organism, tissue and local signals [1, 2]. Regenerative medicine holds 
the promise of promoting tissue regeneration in the body by therapeutically manipulating 
its natural ability to heal after injury or disease. As a concept, it applies various strategies 
for the management of diseases or healing processes, including the tissue engineering 
triad: biomaterials, cells, and signalling molecules [3-5]. These tools should control the 
swing between tissue regeneration and scar formation, promoting the regenerative 
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pathway and avoiding the formation of fibrotic tissue [2]. In this context, blood 
components and their blood derivatives (BD) formulations can provide a wide range of 
biological elements (cells, growth factors (GFs), cytokines and scaffold-forming 
elements) that are essential in the regulation of wound healing mechanisms [6].   
The use of different types of BD has shown positive clinical effects in several fields 
of regenerative medicine such as in the treatments of tendon injures and pathologies [7], 
cartilage disorders [8], as well as in periodontal [9] and soft tissue [10] wound healing. 
However, the systematic review of the literature shows conflicting results in the 
therapeutic outcomes, mainly due to the lack of standardization and poor characterization 
of formulations, which has led to an open debate on their real potential within the field 
[11, 12]. Indeed, BD are a variable pool of cellular, sub-cellular and molecular 
components, making it difficult to draw strong conclusions on which formulation and 
therapeutic regime should be applied in a specific regenerative strategy. To overcome 
these limitations, the development of more controllable systems for the delivery of well 
characterized populations of biomolecules will certainly improve many clinical aspects 
on the use of BD. In vivo, GFs are protected and stabilized via their binding to different 
extracellular matrix (ECM) components [13] that regulate their availability and signalling 
[14]. In a biomimetic strategy, researchers have combined BD with different biomaterials 
to modulate the delivery of bioactive molecules in order to guide the wound healing 
process. 
In this review, we provide a theoretical and investigational framework to improve 
our understanding on the use of BD to modulate the wound healing process towards tissue 
regeneration as opposed to simple repair. Firstly, it is presented a brief overview of the 
fundamental molecular mechanisms of wound healing and tissue regeneration (section 2). 
Subsequently, in section 3, it is provided a general introduction to the methods of 
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preparation and classification of the different BD. In section 4, the recent strategies and 
findings on the modulation of BD delivery in a spatio-temporal, selective and 
concentration-dependent fashion are analysed in detail. In the final section (section 5) 
unresolved issues are critically discussed, providing possible directions for the 
progression of the field looking towards the future. 
 
2.   Mechanisms of wound healing and tissue regeneration 
The natural reaction to injury is the immediate activation of the wound healing 
cascade, which primarily intends to restore tissue integrity and homeostasis. In healthy 
individuals, this process is relatively fast and effective, although it is often associated with 
scar formation, which can be unesthetic and impair the tissue function [2, 15]. Research 
in the field of cutaneous wound healing [16] has made significant contributions to unveil 
the fundamental principles of wound repair and regeneration processes [1, 2]. 
Nevertheless, wound healing stages and key principles are shared among different tissues 
[2, 17]. For example, the events that follow a myocardial infarction are remarkably similar 
to that following a tendon or cartilage injury, a spinal-cord injury, a burn or a gunshot 
wound despite the different types of insult, the different organs affected, and the sterility 
of the wound [2, 18, 19].   
Wound healing can be divided in three overlapping phases: (i) haemostasis (seconds-
minutes) and inflammation (hours-days); (ii) proliferation or new tissue formation (days-
weeks); and (iii) tissue remodelling (weeks-months-years, depending on wound type), 
(Fig. 1). This response can lead to the perfect regeneration of injured tissues and organs 
in some organisms, in contrast to simple repair of the damaged tissue. Although 
researchers have started to establish tissue-specific features of regeneration, the 
heterogeneity among different organisms and tissues is not well understood. Indeed, these 
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complex processes are orchestrated by multiple cytokines, chemokines, and GFs secreted 
by multiple cell types, including platelets, neutrophils, macrophages, fibroblasts, 
endothelial and resident stem cells [2, 17].  
 
2.1. Inflammatory phase 
Immediately after tissue damage, the coagulation cascade is activated to prevent fluid 
and blood loss, leading to haemostasis. The extravasation of blood components triggers 
the formation of a platelet plug followed by a fibrin matrix, which provides a provisional 
scaffold for cell infiltration and proliferation [20, 21]. At the same time, toll-like receptors 
at immune cells surface are activated by blood extravasation elements, ECM degradation 
products and bacteria. This causes the downstream activation of transcription factor 
nuclear factor kappa B, which induces the expression of proinflammatory mediators [18].   
Platelets not only participate in the clot formation but also release large amounts of 
a wide variety of cytokines, chemokines, and GFs, extending their role beyond 
haemostasis to the participation in the innate immune system [22], inflammatory response 
[23], and tissue repair and regeneration [24-27]. 
Neutrophils are recruited to the wound in response to the activation of complement 
cascade, the degranulation of platelets, and bacterial products. These immune cells 
sterilize the wounds, phagocytizing bacteria and clearing cellular debris at the sites of 
tissue damage. However, its excessive activation may result in the killing of many 
otherwise-healthy host cells, a behaviour which is particularly prevalent in chronic wound 
situations [28]. In addition, neutrophils activate other cells through the release of 
inflammatory mediators, such as transforming growth factor-β 1 (TGF-β1), interleukin 
(IL)-1 and -4. As a key player in the initial inflammatory phase, TGF-β1 induces the 
expression of proinflammatory genes that activates the recruitment of monocytes. At the 
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injury site, monocytes differentiate into macrophages, which phagocytize dead cells and 
debris and coordinate tissue repair [28]. Macrophages also produce numerous cytokines 
(IL-1 and IL-6) and GFs (fibroblast growth factor (FGF), endothelial growth factor 
(EGF), TGF-β1, and platelet derived growth factor (PDGF)) crucial for fibroblast 
recruitment and angiogenesis in the proliferative phase [29]. As the first inflammatory 
phase ends, pro-inflammatory macrophages (M1 macrophages), in response to IL-4, 
adopt an anti-inflammatory and reparative phenotype (M2 macrophages) to finalize the 
inflammation [30]. 
 
2.2. Proliferative phase 
The proliferative phase consists on the formation of granulation tissue, ECM 
deposition, and angiogenesis. An interleukin in particular, IL-6, has important functions 
in the new tissue formation phase. IL-6 binding to its receptor activates the signal 
transducer and activator of transcription – Janus kinase pathway, which indirectly induces 
neutrophil and monocyte infiltration, fibroblasts migration and collagen deposition, and 
promotes angiogenesis by the induction of TGF-β1, IL-1, vascular endothelial growth 
factor (VEGF), and hepatocyte growth factor (HGF) production [34]. In the case of skin, 
early migration of keratinocytes into the fibrin matrix leads to re-epithelialization. This 
process is aided by fibroblasts, which, attracted by TGF-β1, among others, invade the 
fibrin network and progressively replace it for a collagen-rich connective tissue [25]. This 
provisional matrix or granulation tissue, invades the wound space and serves as a support 
for angiogenesis and later collagen remodelling [16]. Simultaneously, endothelial cells 
migrate into the wound attracted by VEGF and FGF-2 to form new blood vessels. Some 
fibroblasts undergo transformation into contractile myofibroblasts through TGF-β1 
pathway. These cells secrete copious amounts of collagen and express a-smooth muscle 
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actin, which allows the physical contraction of the wound [35, 36]. However, excessive 
activation of myofibroblasts has been related to fibrotic diseases [37]. 
 
2.3. Remodelling phase 
The final phase of wound repair involves a decrease in cellular content and is 
characterized by significant collagen remodelling. Most of the endothelial cells, 
macrophages, and myofibroblasts undergo apoptosis or exit the wound [2] while collagen 
type III in the ECM is replaced by stronger collagen type I [17]. Remaining cells 
coordinate this process producing new collagen, matrix metalloproteinases (MMP) and 
their inhibitors, tissue inhibitors of metalloproteinases (TIMP), which work together to 
form collagen bundles and achieve the native tissue structure and strength [38]. In 
conclusion, a proper balance between degradation and synthesis of ECM is indispensable 
for normal wound healing. However, the repaired ECM of mature scar tissue differs 
considerably from that of unwounded tissue and is generally characterized by their 
comparatively lower biomechanical properties and functionality [45].  
 
2.4. Towards Tissue Regeneration 
In some eukaryotic organisms, the response to injury can completely recapitulate the 
original tissue architecture through regeneration. Though this process is poorly 
understood, researchers are beginning to uncover the individual components of tissue 
regeneration trough the study of animal models of regeneration and human tissues with 
self-regeneration ability [46].  
A leading hypothesis is that immune cells have a prominent role in the swing between 
regeneration and repair [28]. Efficiently regenerating organisms, such as zebrafish, 
depend on macrophages to efficiently resolve inflammation and facilitate tissue 
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remodelling and regrowth [31]. Furthermore, recent findings indicate that the sequential 
conversion of macrophages from M1 to M2 phenotype might have an important role in 
tissue regeneration [30]. For example, in skeletal muscle, the polarization of M2 
macrophages promotes the release of IGF-1, that supports satellite cell growth and fusion 
to form new muscle fibres, and IL-10 and TGF-β, that suppress inflammation, stimulate 
angiogenesis and promote ECM remodelling, suggesting that modulation of macrophage 
polarization could improve muscle regeneration [47, 48]. Indeed, inflammation is 
necessary for the effective defence against pathogens and to set in motion the tissue repair 
mechanisms following injury, although excessive inflammation delays healing and results 
in increased scarring, compromising tissue regeneration [33].  
As an example of the role of GFs in tissue regeneration, researchers showed that IGF 
and FGF signalling pathways are up-regulated during the fin regeneration in zebrafish. 
TGF-β family members have as well an important role in the balance between wound 
repair and regeneration [36, 39]. While TGF-β1 increases the expression of genes 
associated with ECM synthesis in fibroblasts, it also down-regulates MMP-1 [40] and 
induces the acquisition of the contractile myofibroblast phenotype to close the wound [35, 
41], showing both anti-inflammatory and profibrotic activity. In addition, TGF-β1 is also 
involved in the up-regulation of the angiogenic VEGF expression [42, 43]. On the other 
hand, while TGF-β2 plays a similar role to TGF-β1, the third isoform TGF-β3, inhibits 
scarring and promotes better collagen organization in vivo [44]. In a clinical scenario, 
wounds that heal by scar formation, as opposed to tissue regeneration, have been shown 
to produce increased amounts of TGF-β [2].  
In addition, the liver is one of the few organs in the human body that regenerates 
efficiently after acute or even repetitive damage. Non-parenchymal cells in the liver, 
including macrophages and endothelial cells, are central in the coordination of the 
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regenerative process. In particular, activation of VEGF receptor-2 in endothelial cells, 
stimulates the production of angiocrine factors and HGF, triggering hepatocyte 
proliferation and liver regeneration [49]. 
Mammals have retained much of the molecular machinery used by efficiently 
regenerating organisms, but their regenerative potential is only limited. In part, this seems 
to result from the rapid formation of fibrotic tissue, which probably conferred a survival 
advantage but prevented subsequent tissue regeneration [2, 46]. In order to improve 
human health, GFs from BD could be a potential therapeutic strategy to transform fibrotic 
healing processes into regenerative ones. 
 
 
 
	   12 
Figure 1.  Overview of the classical wound healing phases vs regenerative medicine 
therapy approach. (I) Major wound healing events in a controlled spatial and precisely 
temporal response to injury. (II) The balance of these events plays an important role in 
the swing between tissue repair (scar formation) and tissue regeneration after injury. 
Considering BD content, rich in key biomolecules involved in the regulation wound 
healing mechanisms, its use will potentially alter the outcomes of this process. Adapted 
with permission from [2]. Copyright 2008, Nature Publishing Group. 
 
3.   Preparation and classification of blood derivatives 
Blood is composed of different cellular, sub-cellular and molecular components that 
are involved in essential stages of wound healing [50-52] and regenerative processes [53-
55]. The separation of blood components results on the easy and fast production of 
different BD formulations, being classically produced by the double centrifugation 
technique (Fig. 2) [56]. Generally, it starts with a whole blood centrifugation, called the 
hard centrifugation, in order to separate the blood into three phases: 1) a lower layer rich 
in red blood cells (RBCs); 2) an interface layer (buffy coat) rich in white blood cells 
(WBCs) and platelets; and 3) an upper layer corresponding to the blood plasma with 
platelets in suspension (Fig. 2-IA).  Alternatively, if an anticlotting agent (e.g. heparin or 
citrate) was previously added, it can be collected (alone or in combination with the buffy 
coat) and submitted to a further centrifugation step, called the soft spin (Fig. 2-IC), to 
produce a fraction poor in platelets (platelet-poor plasma (PPP)) and a fraction rich in 
platelets (platelet concentrate (PC) or platelet rich plasma (PRP)) [56]. Table 1 
summarizes the most relevant biomolecules found in BD with therapeutic interest along 
with their main cellular sources. These soluble factors regulate important cell functions 
such as chemotaxis, proliferation and differentiation [53-55]. Moreover, some BD are 
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rich in structural proteins, such as fibrinogen [57] (or its polymerized product fibrin), and 
fibronectin [58], which may act as a provisional matrix for cell adhesion and migration 
[52]. Fibrinogen of platelet concentrates is commonly activated by calcium and exo- 
or/and endogenous thrombin producing a stable fibrin matrix [59]. Both the fibrinogen 
content and activation strategy have a marked impact over the physical properties of the 
resulting fibrin matrix, namely on the fibre diameter and network density that will define 
the in vitro and in vivo stability of the clot, its mechanical properties and its ability to 
sequester the bioactive molecules released by the platelets [60]. Additionally, BD have 
also been reported to exhibit antimicrobial properties [61-64], attributed to the presence 
of β-lysin [65], neutrophil activating protein-2 [66, 67], CXC chemokine ligand-4 [68, 
69], or complement proteins [64] which can contribute for maintaining the prophylaxis 
of the wound site. 
The lack of standardization in origin (auto-, allo- or xenogenous) and preparation 
methods (donors number, anticoagulant agent, activation method) of BD generally leads 
to marked differences in the composition of the formulations, particularly in terms of 
cellularity mainly characterized by the platelet concentration and the presence/absence 
and concentrations of WBCs and RBCs [60, 70-72]. At the end, the presence, 
concentration, protection, release and diffusion of bioactive molecules of interest (Table 
2) from BD will be affected by all these parameters and therefore, their preparation is of 
utmost importance as the first step to control and ultimately achieve the aimed therapeutic 
effect. 
  
3.1. Platelet-poor blood derivatives 
The PPP is a liquid solution of blood plasma with very low cellular content. It is 
obtained, as above described, from whole blood supplemented with an anti-clotting agent, 
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after cycles of centrifugation The PPP is generally used in clinics mainly as a wound 
patch termed as fibrin glue (FG), after induction of the coagulation cascade (Fig. 2 -ID) 
[56]. It has been shown to be haemostatic and to improve the wound healing [73]. FG is 
produced by polymerizing the fibrinogen contained in PPP with thrombin and calcium 
[73] or other coagulation activator. Given the low platelet content, FG is almost depleted 
of GFs of platelet origin (summarized in table 2) [74, 75], although some GFs, such as 
insulin growth factor-1 (IGF-1) and HGF, can be found in FG [74]. Despite the lack of 
GFs of platelet origin, FG was shown to be more effective than activated PRP or PRF for 
the preservation of sockets with buccal dehiscence [75]. The authors hypothesized that 
the absence of anti-morphogenic factors of platelet origin, such as the PDGF [76], and 
the higher fibrin content (Table 2) [75] would enhance the osteoconductive and/or 
osteoinductive properties of FG over PRP and PRF. 
 
3.2. Platelet-rich blood derivatives 
As mentioned before, the fraction rich in platelets is termed as platelet-rich BD. 
During the last two decades, several platelet-rich BD have been developed using the same 
generic name “PRP”. Further than the nomenclature controversy, the ambiguous 
outcomes reported for the in vitro and clinical application of these different “PRPs” have 
early unleashed the discussion on the need of an adequate classification method [56, 60, 
77].  
 
3.2.1. Platelet-rich plasma 
PRP is generally defined as a volume of autologous plasma with a platelet 
concentration above blood baseline (between 1.5x105 /µL and 3.5x105 /µL) [56]. PRP can 
be used directly as a liquid formulation or activated through different methods, including 
	   15 
the addition of thrombin [78], thromboplastin [79], calcium salts [78-81] or collagen [82] 
promoting the formation of a fibrin network containing activated platelets, termed platelet 
gel (PG) (Fig. 2 –IE) [83]. The supernatant, a solution of GFs released upon platelets 
activation in blood plasma, herein termed plasma rich in growth factors (PRGF), has also 
been explored [55, 62]. The activation of platelets contained in PRP induce the 
degranulation of α-granules and the release of several cytokines and growth factors, 
including TGF-β-1 and -2, PDGF-A and -B, EGF, VEGF, and FGF [55, 74, 84, 85] (Table 
1). However, their relative concentration varies considerably between batches and 
activation products. 
Four major factors were identified to influence the composition of the PRP and PRP 
products: 1) the platelet content; 2) the presence of other cells of blood origin, namely 
WBCs; 3) platelet activation protocol; and 4) donor-to-donor variability. The first three 
factors are the basis for most of the PRP classification systems, namely those proposed 
by Ehrenfest [77] and DeLong [86]. Nevertheless, among these factors, platelet content 
will have a major effect in the concentration of GFs of platelet origin [87], and thus in the 
possible therapeutic outcomes. Therefore, Marx and colleagues [56] proposed that, for 
clinical applications, PRP should be defined as a concentration of platelets with a 
consistent therapeutic efficacy, while all the suspensions of platelets in plasma above the 
blood baseline could be generally termed PC. Since the concentration of platelets that has 
been proven to have therapeutic efficacy for bone healing is around 1x106 /µL [56, 88], 
this has been proposed as the platelet content that defines a platelet suspension as PRP. 
However, in literature, some works using products termed “PRP” either overlook the 
platelet concentration [89] or use PC with different platelets concentration [90]. 
Commercially available kits (e.g. PRGF®-Endoret®, PCCS®, Harvest® SmartPrep®) 
have aimed at establishing good manufacturing practice protocols for PRP derivatives 
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production, particularly to reduce the protocol-related variability. Nevertheless, different 
PRP preparation kits still yield significantly different platelets concentration [87, 90]. For 
example, the preparation of PRP from a single donor using PCCS® or PRGF® kits 
yielded differences in leukocytes, platelets and GFs content. PCCS® collects 1,641,800 
± 426,820 platelets/µL, which results in a significantly higher content of TGF-β1 and 
PDGF-AB, in comparison with PRGF® that collects 513,630 ± 139,470 platelets/µL [90]. 
These results might be explained by the collection protocol, since in the PRGF® kit the 
buffy coat (contains leukocytes and platelets) is not used and a second centrifugation 
(hard spin for platelet concentration) is not performed. Therefore, differences in the PRP 
preparation method might explain the conflicting therapeutic results [11], which 
emphasizes the need to standardize the platelet concentration and/or the use of a pool of 
donors to obtain reliable therapeutic effects.  
The leukocytes, mainly neutrophils and macrophages, are usually isolated from the 
whole blood together with platelets during PRP preparation [91]. These cells can 
contribute with cytokines, GFs and proteases involved in the modulation of inflammation 
and clot remodelling [92-94] (Table 1). Based on the potential effect of the WBCs 
content, Ehrenfest and co-workers have defended the necessity to classify PRP based on 
their leukocytes content: leukocyte-rich PRP (L-PRP) and the leukocyte-poor PRP or 
“pure”-PRP (P-PRP) (and, generalizing, all the platelet-rich BD and PRP activated 
products) [60, 77] (Figure 2 -II). Studies comparing the releasate of leukocyte-rich PG 
and leukocyte-poor PG clots, reported no differences in the released concentration of 
several relevant GFs, namely PDGF, VEGF, and TGF-β1 [95, 96] (Table 2). On the other 
hand, due to their higher WBCs contents, leukocyte-rich PG released higher 
concentrations of proinflamatory cytokines, namely IL-1β [95, 96] and TNFα [96].  
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Although results tend to suggest that presence of WBCs in BD might foster undesired 
proinflammatory effects, systematic reviews have shown inconclusive results in the use 
of L-PRP and P-PRP [12]. For example, L-PRP might be less suitable for acute tendon 
conditions because of its catabolic and inflammatory features. On the other hand, P-PRP 
could induce the formation of excessive scar tissue due to its potent anabolic action [97]. 
This exemplifies the current gaps of knowledge on the optimal BD formulations to be 
applied in the treatment of inflammatory diseases or in regenerative strategies. 
Furthermore, there is a clear difference between the PG clot and the PRGF liquid solution 
formulates, mainly because of the platelet activation protocol. Besides the fibrin content, 
differences can be observed in the concentration of some growth factors [74] (Table 2). 
For instance, while the concentration of TGF-β1 is pretty similar between PG and PRGF 
obtained by PRP activation with either calcium or thrombin, the concentration of e.g. 
EGF is consistently higher in PRGF than in PG regardless the activation method [74], as 
a result of their different affinities for the fibrin matrix [98]. The activation method has 
also been shown to influence the structural characteristics of PRP activated products and 
consequently the composition of their releasates. PG clots formed using type I collagen 
exhibited far less retraction than those formed with bovine thrombin [99]. Moreover, 
while both PGs activation protocols resulted in similar PDGF and VEGF release profiles 
between 1 and 10 days, thrombin activation resulted in a comparatively higher release of 
TGF-β1 during the first 5 days [99]. 
Finally, there is a considerable variability between the proteins released from 
different platelet donors [74, 100], which should be a major concern when PRP is 
envisioned for autologous therapies. For instance, Kalén and co-workers observed a 
remarkably high variability between donors on the release of bone morphogenetic 
proteins (BMPs)-2, -4, -6, and -7 from P-PRP [100]. In fact, platelets of only one of thirty 
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donors released BMP-2 at physiologic pH [100]. This variability is of paramount 
relevance for GFs with a major function in the regeneration of the targeted tissue such as, 
in this particular case, the activation of BMPs signalling pathway for osteogenic 
differentiation [101, 102].  In order to mitigate this problem, in last few years the use of 
PRP pools from different donors in alternative to single-donor PRP has been proposed, 
as they yield PRP preparations with more consistent GFs and cytokine contents than 
single-donor batches [74]. 
 
3.2.2. Platelet lysate 
Platelet lysate (PL) is obtained by freeze/thaw cycles [84, 85] or by ultrasounds 
[103] to disrupt the platelets contained in PC batches, either produced by 
centrifugation cycles [85] or by apheresis [84, 85]. PL is a liquid solution of 
biomolecules, and although its platelet content release is obtained by cellular 
disruption instead of α-granules degranulation, it contains most of the GFs 
commonly found in other platelet-rich BD [84, 85]. Nevertheless, the concentration 
of some GFs, namely PDGF, is significantly lower in PL than in PRGF [104] 
(Table 2) emphasizing the relevance of BD production method on their bioactive 
molecules composition. 
PL offer several advantages for therapeutic applications: 1) the clot and platelet 
debris are removed during PL processing, therefore, the PL is a solution that hardly 
forms spontaneously a gel or retracts; 2) the freeze/thaw cycles are easy to 
standardize and do not require the addition of any clot activator to release the 
platelet factors; 3) the concentration of the growth factors and cytokines is highly 
reproducible between batches, which can contribute for more predictable 
outcomes; 4) it can be frozen and stored to be readily available for further use [84]. 
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For TE applications, PL can be processed into a PL gel (PLG) using thrombin 
[103], or loaded into carriers for the sustained release of PL GFs [105, 106]. These 
constructs incorporating PL have shown potential to induce neovascularization 
[103], osteogenesis [105, 106] and to enhance periodontal re-attachment [107]. PL 
has also been proposed as a prevailing alternative to foetal bovine serum 
supplement for culture of several human cell types [84, 108]. 
 
3.2.3. Platelet-rich fibrin 
PRF is a second generation platelet-rich BD proposed by Choukroun [109] as 
an easier to prepare and completely autologous alternative to PRP. Dohan 
classified PRF as an autologous leukocyte-PRF matrix [110] termed L-PRP by 
some authors. Since PRF is produced by the spontaneous coagulation of the upper 
layers obtained after the hard spin of whole blood (Fig. 2 -IB), in addition to 
platelets, it also incorporates all the cells that remain entrapped within the fibrin 
clot, namely RBCs and WBCs [109-111]. In fact, contrarily to other  platelet-rich 
BD which are produced from homogeneous suspensions of platelets, PRF clots 
have a cell gradient starting from the bottom, which is highly rich in RBCs, WBCs 
and platelets, to the top, which is almost depleted from cells [111]. Therefore, the 
WBCs or RBCs content of PRF can be easily reduced by cutting the bottom end of 
the clot [112, 113]. PRF contains several of the GF and biomolecules with 
therapeutic interest found in other platelet-rich BD [111, 113] (Table 2). However, 
the GFs distribution throughout the PRF clot follows the cellular gradient, being 
more concentrated in the lower portion than in the upper portion of the clot [111, 
113]. 
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3.3. Platelet-derived exosomes 
The platelet-derived exosomes (PEx) are extracellular vesicles with sub-micrometre 
diameter (40-100 nm) characterized for expressing the specific markers CD9, CD63, 
CD81 and the marker of platelet origin CD41 [114-116]. Blood circulating exosomes, 
from which the platelet-derived should represent about 25% [117], are known to be 
involved in vascular remodelling [118]. In fact, PEx mediate platelet atherogenic 
interactions with endothelial cells and monocytes [119]. 
PEx are true effectors within the overall platelet function and have been shown to be 
highly modulated by the environmental conditions. They carry several of the most 
important GFs of platelet origin, namely PDGF-BB, TGF-β1, VEGF, and FGF-2 [116]. 
Moreover, PEx incorporate mRNA [114] and might be responsible for the paracrine 
modulation of ICAM-1 gene expression in endothelial cells mediated by miRNAs [119, 
120] (Table 1). Despite being produced constitutively, their number and cargo depend on 
the platelets’ activation process [115]. Aantonen and co-workers demonstrated that the 
activation of platelets with calcium produced higher amount of exosomes than the 
thrombin combined with collagen or lipopolysaccharides activation [115].  
For biomedical applications, PEx can be easily isolated from PL [114] or from 
activated PRP [116] by ultracentrifugation and ultrafiltration. Recent studies 
demonstrated the internalization of PEx by mesenchymal stem cells (MSCs) and its dose-
dependent positive effect on cell migration, and osteogenic differentiation [114]. 
However, before implement PEx as a regenerative medicine approach, future research 
need to explore the content of these vesicles and understand their fundamental role on 
tissue development. 
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Table 1. Summary of cellular, sub-cellular and molecular components of blood 
derivatives relevant for wound healing.  
 Main components Key functions Ref. 
Plasma  
Adhesive 
proteins 
Albumin, globulins, 
fibrinogen, complement 
proteins, and clotting factors 
Haemostasis, clot maturation, 
cell adhesion, activation of the 
immune response 
[74, 121] 
Electrolytes 
Chloride, sodium, and 
calcium 
Haemostasis 
Growth 
factors 
IGF-1, HGF, FGF-2, GH Regulation of cell proliferation 
Platelets    
Alpha granules  
[74, 100, 
120-127] 
Adhesive 
proteins 
Fibronectin, vitronectin, 
fibrinogen, vWF, P-selectin 
Platelet aggregation, platelet-
endothelial cell interaction, 
thrombus formation 
Clotting 
factors 
Factors V, XI, and XIII 
Haemostasis, thrombus 
formation 
Growth 
factors 
PDGF, TGF-β, VEGF, FGF-
2, EGF, and BMPs 
Regulation of cell 
proliferation, differentiation, 
and angiogenesis 
Cytokines / 
Chemokines 
IL4, IL8, TFNα, CXCL4, 
CXCL7, CCL2, CCL3, and 
CCL5 
Chemotaxis, inflammatory 
response modulation, 
antimicrobial activity 
Complement 
proteins 
Complement C3 and 
complement C4 precursor 
Antimicrobial activity 
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Others 
α2-macroglobulin, α2-
antiplasmin, microbicidal 
proteins  
Protease inhibitors, 
antimicrobial activity 
Dense 
granules 
ADP, ATP, calcium, 
serotonin, and 
pyrophosphates 
Platelet activation, 
vasoconstriction 
Lysosomes Proteases, hydrolases 
Matrix degradation, 
antimicrobial activity 
Exosomes 
Adhesion proteins (P-
selectin), genetic material 
(mRNA, miRNA), growth 
factors (VEGF, PDGF, TGF-
β1, FGF-2) chemokines 
(CXCL4, CXCL7) 
Cell adhesion, paracrine 
communication, angiogenesis, 
regulation of cell fate, 
modulation of inflammatory 
response 
Leukocytes   
Neutrophils 
Cytokines (IL-1, IL-4, IL-6, 
and TNF-α), growth factors 
(TGF-β1), and proteases 
Phagocytosis, chemotaxis, and 
matrix remodelling 
[94, 128] 
Monocytes/ 
Macrophages 
Cytokines (IL-6, IL-1β, IL-8, 
IL-10, TNF-α, GM-CSF), 
growth factors (TGF-β1, 
FGF, EGF, PDGF), 
proteases 
Phagocytosis, modulation of 
inflammatory response, and 
matrix remodelling 
Erythrocytes 
ATP, nitric oxide, 
haemoglobin, free radicals 
Vasodilatation, antimicrobial 
activity 
[129] 
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Abbreviations: bone morphogenic proteins (BMPs); C-C motif chemokine ligand (CCL); 
CXC chemokine ligand (CXCL); endothelial growth factor (EGF); fibroblast growth 
factor-2 (FGF-2); granulocyte-macrophage colony-stimulating factor (GM-CSF); growth 
hormone (GH); hepatocyte growth factor (HGF); insulin growth factor-1 (IGF-1); 
interleukin (IL); platelet derived growth factor (PDGF); tumour necrosis factor alpha 
(TNFα); transforming growth factor-β (TGF-β); vascular endothelial growth factor 
(VEGF); von Willebrand factor (vWF). 
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Figure 2. Blood derivatives production and content differences. I. Conventional (manual) 
method for the production of different BD. A) The centrifugation of whole blood (WB) 
induces the separation of the blood components into 3 layers. B) The upper layer, a 
yellowish solution composed mainly of plasma and platelets, coagulates spontaneously if 
no anticlotting agent is previously added to the whole blood, originating a fibrin mesh 
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rich in platelets and leucocytes termed platelet rich fibrin (PRF). C) The whole blood 
supplementation with anticlotting agents allows the upper layer to remain liquid. It can 
be therefore collected (together or not with the buffy coat) and further centrifuged to 
produce platelet-poor plasma (PPP) or platelet concentrate (PC), also called platelet-rich 
plasma (PRP). D) The induction of PPP clotting originates fibrin glue (FG). Likewise, E) 
the induction of PC or PRP clotting originates the platelet gel (PG), and plasma rich in 
growth factors (PRGF). Alternatively, F) the platelets of PC/PRP can be disrupted by 
freeze/thaw cycles or by ultrasounds, originating a solution of platelet lysate (PL), which 
can produce platelet lysate gel (PLG) by fibrinogenesis activation. II. Diagram depicting 
the relative cellular content of each blood derivative and their precursors, compared to 
the physiologic levels (---) in whole blood, throughout the preparation and activation 
processes. 
 
Table 2. Qualitative comparison of the most relevant GFs and fibrin present in BD 
relative to the physiological blood serum levels..  
 Growth factors Blood serum levels (ng/mL) 
Platelet-
poor BD Platelet-rich BD PEx 
Refs 
 PPP PRGF PRF PL 
[57, 64, 
72-74, 92, 
94, 104, 
116, 130-
139] 
 
PDGF-BB 3.84 ± 2.47 -  ++ + + +++  
 VEGF 0.17 ± 0.06 - + + + +  
 
TGF-β1 25.42 ± 5.4  -  + + ++ +++ 
 
FGF-2 0.0055 ± 0.0043   - +++ +++  +++  +++ 
 IGF-1 74.37 ± 47.63   + + +  + u 
 
EGF 0.07 ± 0.06  -  +++ u +++  u 
 
Fibrin/fibrinogen 
(plasma) 2.4 ± 1.4 x 10
6  + N/A ++ -   N/A 
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Abbreviation: “-” ≤ 1-fold; “+” > 1-fold; “++” ≥ 5-fold; “+++” ≥ 10-fold "N/A" non-
applicable; “u” unknown.  
	   27 
4.   Modulation of blood derivatives delivery  
Along the last few decades, the use of BD formulations in clinical applications has 
relied on 1) direct injection of a liquid form and activation by tissue collagen and 
thromboplastin, which form a gel in situ [140]; or 2) induction of the coagulation cascade 
prior to administration to produce a fibrin matrix-based scaffold [141]. Despite the 
numerous positive reports on the use of BD as biomaterial free strategies in tissue 
regeneration and decades of research on this field, some inconsistent and sometimes 
contradictory results are still frequently found [11]. The clear cause-effect relationship of 
these results is difficult to establish due to the complexity and also conflicting presence 
of multiple biomolecules in these formulations, showing that new strategies are necessary 
to overcome these limitations. 
As previously described, the normal wound healing process involves the formation 
of a fibrin network that acts as a sequestering matrix for the blood cellular components 
and its secretome, while providing a temporary scaffold that will support tissue repair. 
This matrix protects the bioactive soluble cargo from fast clearance and proteolytic 
degradation, thus, controlling its release profile, which will ultimately dictate the overall 
wound biological response. In a biomimetic regenerative medicine approach, the 
combination of BD with biomaterial platforms might enable the control of the 
spatiotemporal and selective delivery of signalling biomolecules [2]. This strategy would 
potentiate their therapeutic effect and enhance tissue healing, shifting the normal 
reparative response, generally leading to non-functional scar tissue formation, towards a 
regenerative outcome (Fig. 1). This concept is being developed using a wide range of 
natural and synthetic polymers, inorganic materials, or their blends combined with BD. 
Several strategies have been explored to tune the biomaterial/BD interactions ranging 
from BD covalent (chemical or enzymatic crosslinking) and non-covalent immobilization 
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(affinity-based systems, including electrostatic/ionic interactions, hydrogen bonding and 
van der Walls forces, mimicking the ECM binding mechanisms) to simple physical 
entrapment [14, 142]. Therefore, each specific combination of biomaterials and BD will 
show unique biomolecular binding affinities and release profiles, suggesting that 
numerous engineering possibilities are open to be explored within this field [143-148]. In 
addition to the biological cues provided by BD, biomaterial intrinsic properties (physical, 
mechanical and chemical cues) can also add an additional level of control over cellular 
behaviour (recently defined as Materiobiology) [149], and therefore synergistically 
potentiate the regenerative process.  
In this section, we survey the application of specific combinations of biomaterials 
with BD that are intended to deliver bioactive molecules in mechanisms mimicking the 
cascade of natural signalling events guiding to wound healing process. These include 
strategies to control the selective, temporal, spatial, and concentration-dependent release 
profiles of BD biomolecules in order to foster tissue/organ regeneration (Fig. 3 and Table 
3). It should be noted that strategies comprising only components of the BD, are not under 
the scope of this review. For further information on the topic the readers are referred to 
other recent and comprehensive reviews [6, 108, 150-152].  
 
4.1. Temporal profile 
The time frame in which a beneficial therapeutic effect can be achieved with 
bioactive molecules is limited. For example, soluble GFs have short in vivo half-lives (in 
the order of minutes), degrading or being deactivated via several distinct pathways, 
including denaturation, oxidation or proteolysis, which restricts their dose and temporal 
bioactivity [144, 147]. On the other hand, the extended presence of GFs within a local 
microenvironment can lead to abnormal tissue growth. Therefore, the modulation of the 
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temporal delivery profile of bioactive molecules from BD is crucial to control their 
therapeutic efficiency during the wound healing phases.  
Nano - and micro-particles based carriers have been widely used in drug delivery and 
tissue engineering approaches in order to protect the cargo and control its release to the 
cells’ extracellular fluid or directly within the cells [153-155]. These type of carriers have 
also been explored for the controlled deliver of BD. For example, PL was adsorbed on 
the surface of positively charged chitosan/chondroitin sulphate nanoparticles prepared by 
polyelectrolyte complexation of the two oppositely-charged polysaccharides [105]. 
Chitosan, a bioresorbable and positively charged natural polymer, has been traditionally 
applied to develop different carrier systems and has shown to be able to regulate the 
release of bioactive agents, including GFs [156, 157]. On the other hand, chondroitin 
sulphate is an anionic sulphated glycosaminoglycan that act as a stabilizer and also 
interacts with different biomolecules in the ECM [158]. Exploring their polyelectrolyte 
nature and biological function, chitosan/chondroitin sulphate nanoparticles allowed to 
modulate the temporal release profile of electrostatically adsorbed PL proteins which 
extend up to 1 week.  As the nanoparticles undergo fast cellular internalization (in part 
due to their positive surface charge) , this system might be applied as an intracellular 
delivery vehicle of PL bioactive agents [105]. Interestingly, besides their application as 
carriers, these nanoparticles were also used to produce three-dimensional (3D) structures. 
In a bottom-up strategy, chitosan/chondroitin sulphate nanoparticles loaded with PL 
spontaneously self-assembled (at high concentrations) into stable 3D structures, 
simultaneously entrapping human adipose-derived stem cells (hASCs) [159]. The system 
showed an initial burst release of PDGF-BB and TGF-β1 after one day (92% and 80% of 
their initial amount). This release pattern was correlated with the higher hASCs 
proliferation observed at early time points, compared to cultures on unload particles and 
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in form of cell pellets. The PL function was not only to be a source of bioactive molecules, 
but also acted on the physical stabilization of the system, creating a more appropriate 3D 
environment for hASCs survival and ECM synthesis. In contrast, the incorporation of the 
aforementioned nanoparticles within scaffolds (foams processed by supercritical CO2) of 
poly(D,L-lactic acid) slowed the initial burst release of PDGF-BB, TGF-β1 and VEGF to 
50% after one day, prolonging its sustained delivery up to 28 days [160]. The 3D hybrid 
scaffolds promoted the earlier osteogenic differentiation of hASCs compared to the 
controls, demonstrating the potential of the proposed combinatory approach for bone 
regeneration. Similarly, PL adsorbed on microparticles of hyaluronic acid (HA), a 
negatively charged non-sulphated glycosaminoglycan, were incorporated in calcium 
phosphate cements pastes for bone regeneration applications [106]. The use of HA 
microparticles as carrier clearly maximized the amount of PL that is possible to load into 
the composites cements without affecting their setting properties and also had a 
significant impact on the protein release profiles. Compared to direct mixing with the 
cements, the preloading of PL into HA microparticles resulted in higher total protein but 
lower TGF-β release from the composite. Interestingly, the osteogenic potential of the 
system was enhanced when PL was directly mixed with the cement formulation, which 
might be correlated with their higher release rates of TGF-β. These studies are 
representative of how biomaterial engineering strategies may explore the electrostatic 
interactions between proteins and polyelectrolyte polymeric matrices to modulate the 
release kinetics of BD molecules. For example, albumin, which is the main soluble 
protein of PL [161] and has an acidic isoelectric point (at pH 4.7), is expected to be non-
specifically adsorbed and easily washed out from negatively charged polymers, such as 
HA [162]. On the other hand, since most of the GFs present in PL with therapeutic interest 
have basic isoelectric point (e.g. TGF-β at pH 8.90; PDGF-B at pH 9.39), they can 
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electrostatically bind to negatively charged polymers, such as sulphated 
glycosaminoglycan, as it naturally occurs in the native ECM [163].  
The different processing techniques applied to incorporate BD into scaffolding 
biomaterials has also shown to significantly impact the temporal release profile of GFs. 
For example, in chitosan based scaffolds produced by freeze-drying, adding PRP to 
chitosan gel before the freeze-drying process improved the scaffold structural properties  
and provided a more controlled release of PDGF-BB, IGF-1 and TGF-β1 for 20 days, as 
compared to PRP post-embedding in the scaffold [164]. On the other hand, no major 
differences were observed when PL was loaded before or after freeze-drying in sponge 
scaffolds made of chitosan glutamate, sericin and glycine, both showing similar positive 
outcomes in an ex vivo human skin biopsy model [165].  
During the last few decades, hydrogels became one of the most popular types of 
biomaterials in TERM due to their inherent similarities (structural, chemical and 
compositional) with the native ECM of soft tissues [166, 167]. A representative example 
of this strategy is the recently proposed photoinducible imine crosslinking hydrogel glue 
system based on the imine crosslinking of o-nitrobenzyl alcohol modified-HA (which 
generates aldehyde groups upon light irradiation) with amine groups of the proteins 
present on autologous PRP and also with the tissue surface [168]. The proposed system 
allowed the sustained release of PDGF, TGF-β and FGF over 14 days, alleviating the 
burst release of GFs (2 days) observed on PG (thrombin activated). These differences 
might be explained by the fact that platelets in the hydrogel were not disrupted while 
platelets in PG were activated with thrombin, which leads to fast platelet content secretion 
[169], but also by the positive contribution of the modified-HA matrix on the 
sequestration of platelet-released GFs. Considering that platelets secrete 80-100% of their 
content during the first hour after activation [169], these results tend to suggest that the 
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incorporation of inactivated platelets (PRP) in a hydrogel matrix might prolong the 
sustained release of bioactive molecules, improving the overall wound healing in the 
long-term. Interestingly, the aforementioned HA-PRP hydrogel also enhanced 
chondrocyte and stem cell long-term proliferation and migration, resulting as well in 
stronger tissue adhesiveness and integration in vivo than PG formulation [168]. In a 
different application, freeze-dried chitosan solubilized in L-PRP was used to form stable, 
non-retracting and homogenous injectable implants that coagulate in situ [170]. In a 
subcutaneous animal model, these chitosan-PRP implants remained physically stable for 
at least 2 weeks, while PRP controls lost up to 80% of their original mass and were quickly 
degraded in one day. Moreover, the chitosan-PRP formulations induced cell recruitment 
(macrophages) and angiogenesis after 14 days in vivo, suggesting a strong potential for 
their application in meniscus, cartilage or rotator cuff repair.  
The type of BD and their nature (gel or soluble factors) in combination with 
biomaterials might be an interesting option to modulate the GFs temporal release profile 
and sequestering pattern. For example, PG and PRGF (both calcium activated) were 
incorporated into gelatin-nanohydroxyapatite nanofibrous composite scaffolds as a 
coating or lyophilized within the scaffold nanofibers, respectively [171]. Although both 
formulations could release GFs (VEGF and PDGF) during 4 weeks, scaffolds 
incorporating PRGF within the polymer matrix exhibited a steady release profile for both 
VEGF and PDGF whereas PG coated scaffolds exhibited an initial burst release which 
gradually declined over time, demonstrating that BD loading method in the biomaterials 
has a pronounced impact over the release patterns of their bioactive molecules. Overall, 
these results have been showing that by rationally selecting the biomaterials and 
processing technique it is possible to modulate the delivery profiles of biomolecules from 
BD in a time frame that can spam from days (burst release) to weeks (sustained release). 
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Nonetheless, these approaches still present limitations to reproduce the sequential 
presentation and time-dependent release of GFs involved in specific phases of wound 
healing. For example, TGF-β1 promotes cell recruitment during the inflammatory phase, 
however its presence in latter stages induces scar formation. Besides controlling this 
transient release, it is as well important to control the delivery of multiple GFs to allow 
tissue regeneration. Namely, in order to promote angiogenesis at the proliferative phase, 
VEGF and FGF-2 are required to form immature blood vessels. To enable this 
biochemical signalling at the required time, the polymer composition, type of crosslinker 
and crosslinking density can be manipulated to control their swelling behaviour and 
degradation rate. Using an implant composed of PLGA microspheres loaded with BMP-
2 embedded in a poly(propylene) scaffold, which was surrounded by a gelatin hydrogel 
loaded with VEGF, a sequential delivery of angiogenic factors, within the first three days, 
and osteogenic factors, in later stages, was achieved, which resulted in ectopic bone 
formation [172]. Other biomaterials that could be explored in the future are stimuli 
responsive materials (pH, temperature or magnetic fields) that might be used to trigger 
the on-demand delivery of specific biomolecules at desired healing phases [173]. At the 
end, these properties will engineer the temporal release of bioactive molecules to fit in 
the chronologic events of the wound healing process and ultimately enhance the 
regenerative response [142]. 
 
4.2. Spatial microenvironment 
The spatial microenvironment of a healing wound is affected by ECM remodelling, 
autocrine and paracrine cell signalling, and cells fate, including proliferation, 
differentiation, migration and apoptosis [142]. Along with the available tools to engineer 
the intrinsic physical and chemical properties of biomaterials, the precise spatial control 
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over bioactive molecules delivery will more closely recapitulate the heterogeneity and 
physical/chemical gradients occurring in native ECM, and therefore, boost the 
regenerative process. BD have been combined with different scaffold fabrication 
strategies in order to promote cell migration over and to the scaffold, or to produce well 
defined 3D architecture that can better replicate the several length scales of the complex 
architecture of native tissues by the introduction of hierarchical structures in the 
developed composite biomaterials. Representative examples of these strategies are 
highlighted in the next paragraphs. 
 
4.2.1.   Impact on cell migration 
Nano- microfiber non-woven scaffolds show unique architectural characteristics that 
are considered biomimetic analogues of native ECM due to their dimensional similarities 
to natural collagen fibres [174, 175]. These fibres meshes are usually produced by 
electrospinning, resulting in biomaterials with high porosity and surface area-to-volume 
ratios with potential applications in a wide range of tissue engineering strategies. 
However, they are typically based on polymeric biomaterials with limited bioactivity 
[175]. The incorporation of biological cues, such as BD, in their compositions has been 
proposed as a strategy that might promote cellular migration and proliferation, enabling 
an indirect control over cell behaviour [175]. The incorporation of biomolecules into 
electrospun nanofibers can be achieved by simple blending with the polymeric spinning 
solution or using emulsion and coaxial electrospinning strategies [176, 177]. As an 
example of these approaches, PL was blended with chitosan and poly(ethylene) oxide to 
produce electrospun nanofiber meshes [178]. Remarkably, the biological activity of PRP 
was not affected by the processing conditions. Although 70% of total protein content was 
released within 3 hours and the remaining content after 24 hours, the nanofibrous-PL 
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membrane stimulated cell proliferation and, in formulations with higher concentration of 
PL, keratinocytes showed a more spread morphology, indicating a synergistic positive 
effect of nanotopography and biological cues. Liu and co-workers incorporated PRGF 
(using dextran as emulsion stabilizer) into polycaprolactone (PCL)/gelatin nanofibers by 
emulsion electrospinning technique in order to minimize the denaturation of PRGF 
proteins and increase the bioactivity of the scaffolds [179]. Although the release of 
bioactive GFs from the scaffold showed a burst in the first 24 hours, it lasted for nearly 
30 days, resulting in improved proliferation and chemotactic effects on bone marrow 
MSCs, and more interestingly, promoted in vitro chondrogenic differentiation. The 
enhanced bioactivity of the scaffolds was also demonstrated in vivo in rabbit 
osteochondral defects, improving cartilage wound healing and suggesting to have anti-
inflammatory effects in the joint cavity.   
The persistent presence of bacteria and endotoxins at the wound site is known to 
prolongs the inflammatory phase and may lead to chronic wound infections [180]. An 
injectable hydrogel system composed of chitosan and freeze-dried PG (calcium activated) 
combined with antibiotic nanoparticles (tigecycline) was explored as a convenient and 
effective therapeutic alternative to treat chronically infected wounds [181]. Tigecycline 
sustained release inhibited bacterial growth over time and reduced the inflammatory 
phase, whereas the addition of PG enhanced proliferation and migration of fibroblasts in 
vitro. Interestingly, other studies have also shown that the combination of BD with 
biomaterials might have a positive impact on resolving the subsequent inflammatory 
response occurring after their implantation. For example, PRGF (calcium activated) was 
impregnated into gelatin hydrogels incorporating micelles of sphingosine-1-phosphate 
agonist to induce macrophages recruitment [182]. Within 7 days, about 90% of TGF-β1 
and stromal cell derived factor-1 was delivered and both soluble factors were detectable 
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after 14 days in vivo. Gelatin hydrogels incorporating micelles and PRGF recruited higher 
number of macrophages that lead to an initial increase of pro-inflammatory cytokines 
(TNF-α) level, while 10 days after implantation they increased the production of anti-
inflammatory cytokines (IL-10 and TGF-β1) and osteoprotegerin, an osteoclastogenesis 
inhibitory factor. Thus, sphingosine-1-phosphate agonist and PRGF showed a synergistic 
enhancement effect on the migration and recruitment of macrophages to the wound site 
that modulated the production of inflammatory mediators and induced granulation tissue 
formation and bone regeneration [182]. 
In order to recreate the biological gradients of the ECM, which are known to 
modulate the directional migration and overall cellular physiological behaviour [183], 
photocrosslinkable methacrylated gellan gum was combined with PL to generate 
concentration gradients of bioactive molecules along 3D hydrogel fibres produced by 
microfluidic strategies [184]. Using fibres containing inverse gradients of human 
umbilical vein endothelial cells and PL, it was shown that areas with lower PL content 
decreased cell viability whereas the PL-enriched section increased cell viability and 
induced cell adhesion and colonization after 12 hours and 7 days in culture. In a different 
approach, coating of hydroxyapatite/β-tricalcium phosphate scaffolds with PL also 
showed to increase chemo-attraction and adhesion of MSCs and endothelial cells on the 
scaffold and to induce MSCs to produce and secrete pro-angiogenic proteins [185]. 
 
4.2.2.  Controlled architecture 
The regeneration of complex tissue interfaces has been explored by the combination 
of different materials in biphasic systems. These systems are designed to regenerate both 
the soft and hard regions of tissue interfaces by controlling the gradients of properties that 
define heterogeneous spatial microenvironments [186]. Bi-layered gelatin/β-tricalcium 
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phosphate sponges loaded with either MSCs, chondrocytes and L-PRP (chondrogenic 
layer) or MSCs and BMP-2 (osteogenic layer) were explored to repair osteochondral 
defects of the talus in horses [187]. This study demonstrated that the bilayer sponges 
combined with cell and biological factors promoted significantly higher osteochondral 
regeneration and reduced the defect size, as observed by radiography, quantitative 
computed tomography and macroscopic and histological evaluation 4 months after 
surgery, than the control group (unloaded bilayer sponges). In a similar approach, a 
bilayered system has been explored for the regeneration of periodontium in a critical 3-
wall intrabony periodontal defect in rats [188]. Calcium phosphate cement incorporating 
HA microspheres loaded with PL was used to promote the regeneration of alveolar bone 
side while PL-genipin self-crosslinking membrane was used for the regeneration of 
periodontal soft tissue. The combination of both systems was degraded within 6 weeks 
after implantation, showing a lower epithelial downgrowth and formation of periodontal 
ligament by the immobilization of PL proteins over the tooth root surface [188].  
In recent years, advanced additive manufacturing technologies, such as 3D printing 
and bioprinting,  have emerged in the field of TERM as fabrication strategies that have 
the potential to engineer patient personalized scaffolds and living constructs with finely-
tuned physicochemical properties and tailored components along defined positions of the 
3D space [189]. As an example of the combination of these technologies with the 
incorporation of BD, 3D printed collagen/PCL/bioceramic scaffolds were explored to 
control the release of GFs from recombinant origin and from PRP [190]. After optimizing 
the composition and processing parameters that maximized the osteogenic potential of 
collagen/PCL biocomposite scaffolds and resulted in a sustained release of protein 
biomolecules (tested with BSA), the biomaterials were loaded with bioceramic, 
bioceramic/recombinant human BMP-2 or bioceramic/PRP. Interestingly, the sustained 
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release of bioactive molecules from PRP-loaded formulation resulted in increased ALP 
activity, calcium deposition and osteocalcin activity by osteoblast-like-cells in 
comparison with other control groups, demonstrating that the proposed strategy might 
have the potential to enhance bone regeneration. In an attempt to recreate the different 
length scales and functions of native ECM,  3D printing (microscale control) was 
combined with other fabrication approaches such as layer-by-layer surface coating 
(nano/meso scale control) and freeze-drying (fibrillar structures) to produce 3D 
hierarchical scaffolds for bone tissue engineering [191]. Combining these different top-
down and bottom-up methodologies, 3D printed structures based on PCL were coated by 
layer-by-layer assembly of marine-origin polysaccharides (carrageenan and chitosan) and 
PL, and subsequently freeze-dried to shape the layer-by-layer structures into 
nano/submicron-fibrils and nanocoatings. The sulphated and aminated nature of 
carrageenan and chitosan, respectively, increases the similarity to native ECM, being 
good candidates for the attraction and stabilization of GFs as mimetics of native 
glycosaminoglycans [192, 193].  Remarkably, the PCL- layer-by-layer -PL scaffolds 
could induce the osteogenesis of hASCs without relying on supplementation of culture 
media with osteogenic factors. The promising results of this methodology open the door 
to develop tunable PL hierarchical scaffolds to instruct stem cells towards different 
lineages.  
 
4.3. Selection of specific bioactive molecules  
The ability to control the delivery of specific bioactive molecules is highly important 
to precisely modulate the biological signals of the local cell microenvironment. The use 
of recombinant GFs in combination with finely engineered scaffolds might be a possible 
solution, however these are very expensive strategies having several technical and 
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biological drawbacks [194]. Therefore, the components of BD, a cost-effective source of 
bioactive proteins, might be selectively and non-covalently bond to biomaterials 
constructs following different functionalization strategies.  
Besides structural protein, ECM is composed of proteoglycans containing 
polysaccharides with different sulphation patterns which  specifically interact with 
soluble bioactive molecules and regulates their availability and functionality within 
cellular microenvironment [144, 146]. For example, heparin, a highly sulphated 
glycosaminoglycan, is known to play a major role on  the specific binding, sequestration 
and presentation of GFs containing heparin-binding domains [13]. In a recent work, PRP 
was combined with heparin-conjugated PLGA nanospheres and commercial fibrin gels 
[195]. This strategy prolonged the retention of heparin-binding GFs such as PDGF-BB 
(39% for formulations containing nanospheres vs 88% for PRP control in the first 6 h), 
while preserving their bioactivity. It is reasonable to expect that it might also have similar 
impact on the release profile of other heparin-binding GFs (e.g. FGF-2 and VEGF) 
present in PRP [196, 197].  Furthermore, the proposed system showed superior healing 
outcomes, specifically dermal and epidermal regeneration and angiogenesis acceleration, 
as compared to the controls in a mouse skin wound model [195]. Moreover, PLGA 
degradation produces lactate that accelerates angiogenesis, activates pro-collagen factors 
and recruits endothelial progenitor cells to the wound site, which could have a synergistic 
positive impact on the obtained results [153]. Despite the obvious benefits of applying 
heparin as binding motif for certain GFs, the use of high doses of heparin is associated 
with several health risks due to its anticoagulant activity [198] that should not be 
disregarded in materials design.  
The protein binding specificity of sulphated glycosaminoglycans is highly influenced 
by the sulphation position and patterns [199]. Therefore, the influence of charge and 
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sulphation degree of different polysaccharides on the selective sequestration of bioactive 
molecules from BD have been studied using self-assembled PL-polysaccharide 
multilayered nanocoatings [200]. While the intermediate sulphated polysaccharide (i-
carrageenan) achieved high levels of FGF-2, VEGF and PDGF adsorption, the low 
sulphated polysaccharide (k-carrageenan) adsorbed high amounts of PDGF and 
intermediate levels of VEGF. On the other hand, heparin (highly sulphated) showed only 
high levels of VEGF adsorption while unsulphated polysaccharides (alginate and 
chitosan) general led to the adsorption of low levels of all tested GFs. These results 
highlight the potential of surface engineering strategies to selectively incorporate BD 
components into biomaterials and to modulate cell-material interactions. It is well known 
that the maintenance of adequate concentrations of appropriate biological factors is of 
key importance for the outcomes of the wound healing events. For example, the presence 
of the PDGF is important in MSCs proliferation, however its anti-morphogenic properties 
might impair the bone regrowth [201]. Therefore, in a regenerative approach, highly 
sulphated polymer-PL nanocoatings might be more adequate to promote the 
vascularization of tissue engineered constructs or to induce the vascular differentiation of 
stem cells since they lead to the incorporation of lower levels of PDGF and higher levels 
of VEGF than their less sulphated analogues [200]. This hypothesis has been tested in 
human umbilical vein endothelial cells, where the highly sulphated polysaccharides-PL 
nanocoatings induced cells to rapidly form tube-like structures accompanied by an 
increased expression of angiogenic associated genes [202].  
The immobilization of antibodies on the surface of biomaterials to recognize and 
recruit specific GFs from BD is another design option being explored with impressive 
results. For example, Custódio and co-workers immobilized anti-PDGF-BB antibody on 
chitosan microparticles surface [203]. After incubation of the microparticles with PL, it 
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was observed a significantly decrease of PDGF-BB (68%) in the remaining PL solution, 
whereas the content of VEGF (18%) and TGF-β1 (20%) only registered a slight decrease, 
demonstrating the expected highly selective GF recruitment capability of this strategy. 
Furthermore, the proposed system allowed a faster attachment of hASCs, which lead to 
the formation of 3D constructs after 12 hours while control groups were not able to form 
stable aggregates. Similar approaches have been adopted for the immobilization of 
antibodies on the surface of electrospun nanofibers [177, 204]. With this strategy, it was 
possible to selective bind VEGF, TGF-β1 or FGF-2 from a pool of proteins (PL) without 
affecting its bioactivity [204]. Furthermore, the simultaneous immobilization of multiple 
antibodies, distributed in a mixed or in a spatially controlled fashion, was also shown 
[204]. Although authors did not target any specific tissue, it can be foreseen that this 
strategy can be customized for specific regenerative medicine strategies, allowing, for 
example, the immobilization of GFs in a single or multiple binding approach, or the 
production of GFs patterns and gradients. 
 
4.4. Blood derivatives concentration  
The amount of BD delivered to the wound niche and, thus, bioactive molecules 
concentration, will affect the number of ligand-receptor events occurring in a given time 
frame and the extent of downstream intracellular signalling cascades driving tissue 
regeneration. Although, to the best of our knowledge, the specific GFs concentrations that 
trigger the regenerative pathways are not described yet, previous studies using PRP 
formulations in in vitro cultures, have reported that there is a dose-dependent effect of 
BD concentration on e.g. cell proliferation and differentiation [205], being therefore a 
relevant parameter that should be optimized when combined with biomaterials. For 
instance, collagen/gelatin scaffolds were impregnated with reconstituted freeze-dried PL 
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in order to study the optimal PL concentration (1x, 2x, 3x, or 4x concentrated) to promote 
wound healing in vivo [206]. The release of GFs from the scaffolds increased in a 
concentration-dependent fashion and correlated with the scaffold degradation profile. 
Moreover, the 2x formulation effectively accelerated wound healing, enhancing cell 
proliferation and vessel growth in granulation tissue without obvious inflammatory 
reactions in a full-thickness skin defect. In a similar approach, gelatin sponges with 
different concentrations of PRGF (1x, 3x and 5x) were implanted in alveolar bone defects 
in rats and 3x PRGF sponges enhanced bone regeneration outcomes compared with the 
other formulations [207]. Remarkably, when PRP was used without the gelatin, it 
detached from the injury site and did not contribute to the regenerative process, 
evidencing the importance of biomaterials to allow the retention of BD at the injury site 
and the localized delivery of their signalling molecules.  
More recently, photocrosslinkable methacrylated-HA hydrogels were blended with 
different concentrations of PL (0, 50 and 100%) [63]. Both PL formulations exhibited a 
similar release profile, although the amount of total released protein was proportional to 
the initial amount of protein incorporated in the hydrogels. Surprisingly, the amount of 
FGF-2 released, after enzymatic degradation of the hydrogels, was negatively correlated 
with the initial protein loading. Similarly, PL incorporation positively impacted human 
periodontal ligament fibroblasts proliferation and metabolic activity. Furthermore, using 
the same system, it was possible to safely preserve and store hASCs and PL-derived GFs 
under standard cryopreservation protocols, showing the potential of this system as off-
the-shelf injectable formulation [208].  
The use of remote magnetic stimulation combine with magnetic responsive 
biomaterials might be a novel strategy to modulate the released kinetics in a timely and a 
controlled space that can potentiate the regenerative process [209]. For example, 
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magnetic nanoparticles were incorporated in a methacrylated chondroitin sulphate 
hydrogel loaded with PL. Under magnetic stimulation, PDGF-BB release was faster and 
higher compared to the non-stimulated group. Besides enabling the localized control of 
GFs release, magnetic stimulation showed to modulate the swelling, matrix stability and 
degradation, which in combination with PL bioactivity, had a synergistic impact on cell 
morphology and synthesis of tendon- and bone-like matrix in an in vitro interfacial co-
culture model (hASCs and tendon-derived stem cells).  
 
4.5. Towards a clinical translation 
Previous in vitro and in vivo studies have consistently showed that the combination 
of BD with biomaterials might be a suitable strategy to modulate the delivery of their 
bioactive molecules and maximizes the synergistic biomaterial/BD therapeutic efficacy. 
Some of those therapeutic products are on the way to clinical translation. In this section, 
we review biomaterials loaded with BD that have been or are currently undergoing 
clinical studies for skin, maxillofacial, orthopaedic, and wound healing related 
applications. In a case report, three patients with chronic pressure ulcers were treated with 
PG (calcium activated) and PRP loaded in alginate beads for the sustained delivery of BD 
bioactive molecules [210]. Despite the small patient sample size, this approach increased 
granulation tissue in-growth and vascularity, improving wound healing. In a different 
case study, one patient with a two years nonhealing ulcer was treated with activated PRP 
covered by a gelatin sheet over 5 days [211]. The treatment improved granulation tissue 
formation over the wound. After thirty-three days, a new gelatin sheet impregnated with 
freeze-dried PRP was applied into the injury site, which healed without recurrent 
ulceration after 9 months. In the maxillofacial research area, a clinical study with ten 
patients used PG (thrombin and calcium activated) combined with MSCs and HA scaffold 
	   44 
as a periodontal regenerative therapy for soft-tissue augmentation [212]. No adverse 
effects were observed during the follow-up time and all patients reported high 
satisfaction, demonstrating various degrees of regeneration and defect filling. The 
involvement of progenitor cells in this process might have an influence in the different 
outcomes. Currently, a randomized clinical trial (NCT03227367) composed of healthy 
individuals and chronic periodontitis patients is investigating biphasic calcium phosphate 
combined with PRF for inhibiting osteoclasts differentiation and bone loss [213]. 
 Some commercial products using BD in combination of biomaterials are already 
approved and distributed for musculoskeletal disorders. One example is Vergenix™ STR 
(CollPlant Ltd., Ness-Ziona, Israel) composed of plant derived recombinant human type 
I collagen mixed with PRP for lateral epicondylitis [214]. In the clinical trial, the product 
showed to have a clinical success rate (>25% improvement in pain and motion) 
significantly better than corticosteroids or PRP (standard treatments) and reduction in 
pain and recovery of motion using standard evaluation methodology at 3 months and 6 
months post treatment. Another commercial product, BST-CarGel® (Smith and Nephew, 
MA, USA), is composed of chitosan gel and PRP (uncoagulated) [215]. This medical 
device is used to stabilize the microfracture-based blood clot (standard and first-line 
surgical treatment) and it was shown to be an effective mid-term cartilage repair 
treatment, having a significantly higher therapeutic outcome compared with the 
microfracture alone in a randomized controlled clinical trial. 
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Figure 3. Strategies incorporating blood derivatives into biomaterials in order to 
modulate BD temporal profile: A) PL was loaded into chitosan/chondroitin sulphate 
nanoparticles, adapted from [105]. Copyright 2012, John Wiley and Sons.   B) PRP was 
loaded into sponges composed of chitosan, reproduced with permission [164]. Copyright 
2013, John Wiley and Sons. C) PRP was covalent crosslinked and physical encapsulated 
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into modified HA injectable hydrogels. Reproduced with permission [168]. The control 
over cellular spatial distribution by D) PRGF proteins incorporation in electrospun 
meshes, reproduced with permission [179]. Copyright 2017, Elsevier. E) PRP 
incorporated into 3D printed polycaprolactone scaffold, reproduced with permission 
[190]. Copyright 2017, Elsevier.  Finally, the modulation of selective bioactive molecules 
by EF) polysaccharides presenting different sulphation degrees and charges, reproduced 
with permission [200]. Copyright 2015, Elsevier. BD concentration-dependent delivery 
by G) PL incorporation in magnetic responsive hydrogels, reproduced with permission 
[209]. Copyright 2017, Elsevier. 
 
Table 3. Summary of the most relevant preclinical studies using combinations of BD with 
biomaterials. Abbreviations: PRP (platelet rich-plasma); HA (hyaluronic acid); L-PRP 
(leukocyte PRP); PRGF (platelet rich-in growth factors); PCL (polycaprolactone); FG 
(fibrin gel); Pl (platelet lysate). 
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 Type of material Animal model Major results Target tissue Ref. 
T
im
e 
Autologous PRP 
covalently bound to 
photoresponsive HA 
hydrogel 
Rabbit full-
thickness 
osteochondral 
defect 
In situ hydrogel filled and adapted to the 
injury shape. After 12 weeks, regenerated 
hyaline cartilage integrated well with 
adjacent tissue. 
Cartilage [168] 
Chitosan solubilized 
in allogenic L-PRP 
Subcutaneous 
rabbit model 
Chitosan-PRP implants resided for at least 
14 d and induced cell recruitment 
(macrophages), angiogenesis and showed 
tissue building capacity. 
Meniscus 
Cartilage 
Rotator Cuff 
[170] 
Sp
ac
e 
Autologous PRGF and 
dextran incorporated 
in PCL/gelatin 
nanofibers 
Rabbit full-
thickness 
cartilage and 
subchondral 
bone defect 
Increased collagen II, aggrecan, and Sox9 
synthesis, while decreased collagen I. 
Regenerated cartilaginous matrix was 
observed around the clusters of regenerated 
chondrocytes, and also relieved 
inflammatory reactions. 
Cartilage [179] 
Autologous PRGF 
loaded in gelatin 
hydrogel with 
sphingosine-1-
phosphate agonist 
micelles 
Rat bone 
defect 
Promoted migration and recruitment of 
macrophages and induced granulation 
tissue formation and bone regeneration. 
Bone [182] 
Bilayer sponges: 
gelatin/β-tricalcium 
phosphate loaded with 
MSCs, chondrocytes 
and autologous L-PRP 
or MSCs and BMP-2. 
Equine full-
thickness 
osteochondral 
defect 
4 months after surgery, the defects were 
covered with smooth white tissue. The 
upper part was filled with cartilage-like 
tissue and better bone regeneration was 
observed in the lower part. 
Joint disorder 
(Osteochondro
sis) 
[187] 
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5.   Concluding remarks and future directions 
The use of BD from autologous sources as therapeutic strategies, particularly 
targeting the regeneration of musculoskeletal tissues, rapidly moved into clinical trials 
due to their inherent advantages in terms of translation potential. However, these efforts 
to rapidly translate fundamental science into medical applications lead to the poor 
Bi-layered system:  
allogeneic PL loaded 
in calcium phosphate 
cement with HA- 
microspheres   and 
PL-genipin 
Rat critical 3-
wall intrabony 
periodontal 
defect 
The construct was completely degraded 
after 6 weeks and was substituted by highly 
vascularized aligned connective tissue. It 
restricted the formation of long epithelial 
junctions and enabled the formation of 
periodontal ligament. 
Alveolar bone [188] 
Se
le
ct
iv
e 
Autologous PRP with 
FG loaded in heparin-
conjugated PLGA 
nanospheres 
Mouse skin 
wound model 
 
Enhanced keratinocyte migration, superior 
healing properties (dermal and epidermal 
regeneration) and angiogenesis 
acceleration. 
Skin [195] 
C
on
ce
nt
ra
tio
n 
Allogeneic freeze-
dried PL (1x, 2x, 3x, 
or 4x concentrated) 
impregnated in 
collagen/gelatin 
scaffolds 
Mouse full-
thickness skin 
defect 
2x formulation effectively accelerated 
wound healing, enhancing cell proliferation 
and vessel growth in granulation tissue 
without obvious inflammatory reactions 
Skin (dermis-
like tissue) 
[206] 
Autologous PRGF 
(1x, 3x and 5x 
concentrated) 
impregnated in gelatin 
sponges 
Rat alveolar 
bone defect 
3x PRGF hydrogel increased new bone 
regeneration. 
Alveolar bone [207] 
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understanding of the biological and cellular mechanisms behind their use. The need for 
standardization of PRP preparation methods continues to be a common argument raised 
to explain discrepancies among studies and the lack of efficacy of some PRP based 
therapies in clinical settings [216-218]. While standardization issues may be solved by 
the definition of good manufacturing practice protocols that generate reproducible BD 
formulations and the use of platelets from a pool of donors, establishment of clear 
relationships between the overwhelming numbers of bioactive molecules present in 
different BD formulations with the resulting therapeutic effects may be a herculean task. 
As highlighted in this review, the development of more controllable systems for the 
delivery of a well characterized population of bioactive molecules to target cell niches 
will certainly improve many clinical aspects behind the use of BD.  
The combination of BD with biomaterials has emerged as a synergistic strategy to 
modulate the selective spatio-temporal and dose-controlled release of signalling 
molecules that will orchestrate the swing between tissue regeneration and scar formation. 
Taking in consideration the complex microenvironment present in wound healing, the co-
delivery of several bioactive molecules (e.g. GFs and cytokines) from BD will most likely 
result in a more efficient regenerative microenvironment than the delivery of a single type 
of biomolecule. To date, most of the proposed strategies to deliver and release BD in a 
temporal controlled fashion relied on the use of nano- microparticulate systems as 
carriers. These systems enabled the delivery of encapsulated bioactive molecules in short 
periods (hours), showing a temporary effect. In a bottom-up strategy, the physical 
encapsulation of BD in sponges and hydrogels showed to prolong the release (weeks to 
months) of biomolecules, enhancing their stability and therapeutic efficiency. 
Implementing these relatively simple strategies, it is possible to modulate the release 
profile of different biomolecules by the rational selection of biomaterials (tuning the 
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matrix/biomolecule interactions) and by controlling their degradation rates. However, 
most of these systems remain as proof-of-concept, since their design considerations and 
physicochemical properties still require further optimization. In particular, it is necessary 
to add control over the delivery of multiple bioactive factors at distinct release kinetics in 
order to enable a dynamic temporal release that matches with the wound healing events.  
Regarding the spatial coordination, we have considered systems where the 
incorporation of BD influences cell fate towards tissue regeneration, mainly cellular 
migration, proliferation and differentiation. For example, in 3D hydrogel fibres, BD 
increased cellular colonization and adhesion to the biomaterials as well as cell viability. 
However, these systems have limitations in terms of mimicking the native tissues 
complexity and wound healing microenvironment (different cells types, signalling 
molecules and biochemical/biomechanical properties). The advent of 3D 
printing/bioprinting technologies in TERM applications might help to overcome some of 
the reported limitations by enabling to fabricate customized constructs with precise 3D 
patterns of different biomaterials, cells and signalling molecules [189]. At the moment, 
only a few studies explored the potential of these fabrication techniques in combination 
with BD as bioinstructive cues. Therefore, this is an interesting research topic open to be 
explored in which we foresee major developments in the near future. 
The selective delivery of biomolecules from BD can be modulated by different 
strategies, including the non-covalent immobilization within biomaterial nanocoatings 
(mimicking the natural interactions occurring in the ECM) or by the covalent 
functionalization of the biomaterial surface with antibodies, which enables the specific 
binding of targeted bioactive molecules. In particular, due to their inherent high molecular 
specificity and affinity, the bioconjugation of antibodies to biomaterials is a promising 
approach to selectively bind GFs of interest and modulate cell fate, avoiding the 
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conflicting co-delivery of bioactive molecules with opposite roles that might have an 
undesired outcome, such as anti-morphogenic (e.g. PDGF-BB) and morphogenic factors 
(e.g. VEGF). Antibodies immobilization has however several limitations that hider their 
practical application and clinical translation such as high cost, low shelf stability or the 
associated immunological risk for humans [219]. In order to explore the full potential of 
GFs sequestering biomaterials in combination with BD, molecular imprinting method can 
create in synthetic polymers selective recognition sites for a specific molecular template, 
resulting in materials that mimic antibody combining sites [220, 221]. By exploring the 
molecular imprinting technology, it would be conceptually feasible to produce intelligent 
biomaterials able to remove undesired components or selectively recruit the bioactive 
molecules of interest (single or multiple) from a pool of proteins (BD). Another important 
aspect in order to modulate the selective delivery of GFs is the processing of BD. 
Fibrinogen present in different BD formulations and coagulation cascade inductors will 
have a marked impact over the physical properties of the resulting fibrin matrix and the 
ability to retain and present GFs [59]. Moreover, this will also affect the downstream 
temporal platelet degranulation profile (fast with thrombin and slow with calcium) [169]. 
Thus, different activation strategies will affect GFs bioavailability which will lead to 
differences in wound healing process [163, 222] and to various effects at cellular level 
[61]. 
Due to the emerging research highlighting the importance of cell-derived exosomes 
in tissue development and homeostasis regulation [223], the use of platelet-derived 
exosomes could be a simple and safe alternative to modulate tissue regeneration. 
However, despite their promising benefits, there is still a lack of comprehension on the 
biological relevance of the activation process to produce populations with defined cargos, 
which should be addressed in future research. Additionally, in the authors opinion, future 
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studies should also invest more research efforts on studying the release profile of multiple 
therapeutic molecules (GFs, cytokines and others bioactive molecules) in order to 
improve the general understanding on the affinities between the biological cues of BD 
and biomaterial matrices. This data would provide the necessary knowledge to rationally 
select systems that enable a tissue-specific spatio-temporal, selective and dose-dependent 
release profile of bioactive molecules present on BD, more than only controlling the 
quantity of GFs that is loaded.  
Currently, the major challenge in the field is the translation of these approaches to clinical 
use. Clinical cases are based in small study samples that showed heterogeneous degree of 
regeneration, thus, being difficult to understand the potential of each formulation. Despite 
the fast translation of BD to clinical use, the combination with biomaterials is challenging, 
because they require an approval as new biomaterial-based products, even when using 
materials already approved in other applications due to the different properties and 
possible different outcomes [224]. Although, this process will necessarily slow its 
translation to the clinics, in our opinion, it is the right direction in order to get the best of 
BD’s therapeutic potential.  
Major advances have been made over the recent years to develop these systems, 
but there remain a number of challenges that will need to be addressed in the future. As a 
strategic pipeline, the definition of good manufacturing practice protocols to standardize 
the production method of BD formulations, together with the continuous understanding 
of the basic biology of BD in wound healing modulation will provide robust and 
reproducible therapeutic results.. Moreover, specifically designed biomaterials 
incorporating BD that bind to and sequester biomolecules, and the full understanding of 
the nature of these interactions will enable engineering the wound healing environment 
towards tissue regeneration. 
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